Form 4 for INSM INSMED Inc
Accepted 2026-04-03 16:07:37 ET · period of report 2026-04-01 · accession 0001685904-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-03 16:07 | 2026-04-01 | INSM | Adsett Roger | COO | M - OptEx | $14.56 | +88.1K | 194.9K | +82% | +$1.28M |
| DMT | 2026-04-03 16:07 | 2026-04-01 | INSM | Adsett Roger | COO | S - Sale+OE | $164.63 | -88.1K | 106.8K | -45% | -$14.50M |
| DT | 2026-04-03 16:07 | 2026-04-01 | INSM | Adsett Roger | COO | M - OptEx | $0.00 | -88.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-01 | M | A | 88,060 | $14.56 | 194,870 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 2 | Common | Common Stock | 2026-04-01 | S | D | 6,715 | $163.18 | 188,155 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F2) This is the weighted average sales price representing 6,715 shares sold at prices ranging from $162.52 to $163.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 3 | Common | Common Stock | 2026-04-01 | S | D | 19,001 | $164.11 | 169,154 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F3) This is the weighted average sales price representing 19,001 shares sold at prices ranging from $163.52 to $164.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 4 | Common | Common Stock | 2026-04-01 | S | D | 62,344 | $164.95 | 106,810 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F4) This is the weighted average sales price representing 62,344 shares sold at prices ranging from $164.52 to $165.45 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 5 | Derivative | Stock Option (right to buy) | 2026-04-01 | M | D | 88,060 | $0.00 | 0 | D | $14.56 · — to 2026-10-03 | 88,060 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F5) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |